Anticorps Monoclonal anti-NeutraKine® IL-17A
NeutraKine® IL-17A Monoclonal Antibody for Neutralization, ELISA
Hôte / Isotype
Mouse / IgG1
Réactivité testée
Humain
Applications
Neutralization, Cell treatment, ELISA
Conjugaison
Non conjugué
CloneNo.
1F3E3
N° de cat : 69021-1-Ig
Synonymes
Galerie de données de validation
| Neutralization | cellule HT-1080 |
Informations sur le produit
69021-1-Ig cible NeutraKine® IL-17A dans les applications de Neutralization, Cell treatment, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain |
| Hôte / Isotype | Mouse / IgG1 |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | human Humankine IL-17A protein HZ-1113 |
| Nom complet | interleukin 17A |
| Symbole du gène | IL17A |
| Identification du gène (NCBI) | 3605 |
| Conjugaison | Non conjugué |
| Forme | Lyophilized Powder |
| Méthode de purification | Purification par protéine A |
| Tampon de stockage | PBS stérile. |
| Endotoxin | <0.1 EU/μg |
| Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
| Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Informations générales
IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.
This antibody can be used to neutralize the bioactivity of IL-17A.
Publications
| Species | Application | Title |
|---|---|---|
Int J Chron Obstruct Pulmon Dis IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD | ||
JCI Insight Targeting mTOR with a sirolimus-eluting airway stent reduces pro-fibrotic TH17-cells and inhibits laryngotracheal stenosis |
